The United Nations Removes Cannabis from Schedule IV of the Single Convention – With U.S. Support
Learn about the UN's significant decision to remove cannabis from Schedule IV, with U.S. backing, marking a shift in global drug policy.
Home | Canna Law Blog | The United Nations Removes Cannabis from Schedule IV of the Single Convention – With U.S. Support The United Nations Commission for Narcotic Drugs (CND) voted on Wednesday to accept the World Health Organization’s (WHO) recommendation to remove cannabis and cannabis resin for medicinal purposes from Schedule IV of the 1961 Single Convention on Narcotic Drugs. It was a close vote – passing 27 to 25, with the United States and notable European nations in favor (and China and Russia against). The WHO had made six cannabis-related proposals for the CND’s consideration back in the beginning of 2019, but the CND passed only the one. The Single Convention categorizes drugs based on their possible harm versus medical utility, with Schedule IV including those that are considered the most harmful with virtually no medical utility. The U.S. previously confirmed it would be supporting the WHO recommendation to remove cannabis from the restrictive global drug scheduling category and published a statement about its rationale for the vote: The vote of the United States to remove cannabis and cannabis resin from Schedule IV of the Single Convention while retaining them in Schedule I is consistent with the science demonstrating that while a safe and effective cannabis-derived therapeutic has been developed, cannabis itself continues to pose significant risks to public health and should continue to be controlled under the international drug control conventions. Further, this action has the potential to stimulate global research into the therapeutic potential and public health effects of cannabis, and to attract additional investigators to the field, including those who may have been deterred by the Schedule IV status of cannabis. The statement is pretty consistent and reflective of what we already knew. The market for medicinal use marijuana has exploded in the past decade and that trend is generally expected to continue. And in this post, we laid out how the 2020 election resulted in even more legalized medicinal and recreational marijuana – even in very conservative states. It's important to note this doesn’t mean that countries are now free and clear to legalize cannabis at large. Cannabis still remains as a Schedule I drug on a separate international drug control system. But like the statement suggests, this vote will likely be a monumental symbolic win and encourage research and further legalization efforts on a global scale. The proposal to reclassify was definitely the focus and purportedly the most hotly debated, but the other five proposals that did not pass were: Recommendation 5.2: add dronabinol and its stereoisomers (delta-9-THC) to Schedule I of the 1961 Convention (Recommendations 5.3 and 5.6 were tied to Recommendation 5.2) Recommendation 5.4: delete extracts and tinctures of cannabis from Schedule I of the 1961 Convention Recommendation 5.5: exempt CBD preparations with less than 0.2% THC from international control The opposition to Recommendation 5.5 is probably most notable because it failed to pass on somewhat technical issues. The U.S. cited “legal and procedural grounds” to explain its vote, rather than any belief that CBD should be under the control of international drug conventions: “We do not dispute the scientific basis for the recommendation. Cannabidiol has not demonstrated abuse potential, and it is not our position that cannabidiol should be or is under the control of the international drug conventions … We look forward to continuing the conversation around this important issue within the CND.” So while not a complete win, the U.S. and other countries have made it clear their votes against Recommendations 5.2-5.5 did not stem from a general anti-cannabis posture and they wished to continue developments on an international scale. In any event, this week was likely the first step in a gradual trend of change we expect to see, and that alone is enough cause for some celebration. For more on public international law and the cannabis trade, check out the following: The United Nations is FINALLY Taking a Hard Look at Cannabis The World Health Organization Steps Up on Cannabis International Cannabis: Breaking the Law, Staying Honest U.S. Cannabis and International Trade: Never the Twain Shall Meet? How to Export Medical Cannabis Internationally International Cannabis: Selling Worldwide The World Trade Organization and Cannabis Check Out Our Cannabis Law Services Share Twitter Facebook LinkedIn E-mail Comment Canna Law Blog The Canna Law Blog is a forum for discussing the practical aspects of cannabis law and its impacts on the cannabis industry. We provide insight into how cannabis businesspeople can use the law to their advantage and in plain language we tell you what works and what does not. We aim to help you strategize how to wield the law as both a shield and a sword. Harris Sliwoski Blog Read more posts [email protected] Read More International Cannabis Law, Medical Marijuana Related Posts September 25, 2026 DEA Enforcement in a Changing Cannabis Landscape: Rescheduling, Hemp, and What Comes Next September 17, 2026 The Supreme Court May Decide if Cannabis-Related Residency Requirements are Unconstitutional September 16, 2026 A $31.8 Million Cannabis-Related Verdict That a Federal Court Wouldn’t Enforce September 15, 2026 Jason Adelstone Moderates Federal Cannabis Policy Discussion at IgniteIt Denver September 11, 2026 Medical Marijuana in Schedule III Survives Its First Major Challenge September 10, 2026 How to Acquire a Colorado Cannabis License September 4, 2026 The Intoxicating Hemp Products Ban Was Delayed a Month. Now What? August 31, 2026 Is the Global Shift to the Right Threatening International Cannabis Reforms? August 28, 2026 Oregon Cannabis Roundup: Fall 2026 August 26, 2026 Five Bills Every California Cannabis Operator Needs to Track in 2026 August 14, 2026 California Cannabis Contracts After Rescheduling: Why Your Contracts Need a Second Look August 4, 2026 DCC License Conversions After Rescheduling: How and When to Split A/M Licenses in California August 3, 2026 The Contradictions of Cannabis Law: From the United States to International Treaties July 28, 2026 What California Operators Must Do After Rescheduling: DEA Registration, License Restructuring, and 280E July 24, 2026 Medical Marijuana Schedule III Litigation: The D.C. Circuit's First Major Test Leave a comment Cancel reply